Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy.
Ahizechukwu C EkeSean S BrummelMuktar H AliyuLynda Stranix-ChibandaGeorge U ElejeIfeanyichukwu U EzebialuViolet KorutaroDeo WabwireAllen MatubuTapiwa MbengeranwaNahida ChakhtouraLameck ChinulaKatie McCarthyKevin KnowlesChelsea KrotjeMacrae F LintonKelly E DooleyPaul E SaxTodd T BrownShahin Lockmannull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Pregnant women randomized to start TAF/FTC+DTG had higher lipids than those randomized to TDF/FTC+DTG within eight weeks of ART initiation. However, lipid levels were within normal reference ranges.
Keyphrases
- antiretroviral therapy
- pregnant women
- hiv infected
- hiv positive
- human immunodeficiency virus
- double blind
- hiv infected patients
- hiv aids
- open label
- placebo controlled
- phase iii
- fatty acid
- phase ii
- clinical trial
- pregnancy outcomes
- blood glucose
- type diabetes
- adipose tissue
- weight loss
- men who have sex with men
- hiv testing